Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence
Rattachement africain : ru, us, pl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice. Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment. Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence
- Date Crossref
- 22/04/2025
- Éditeur
- IMA Press, LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Krasnoyarsk State Medical University pays non établi dans la noticeUniversité ou école supérieure
-
City Clinical Hospital pays non établi dans la noticeÉtablissement de santé
-
Regional Clinical Hospital No 4 pays non établi dans la noticeÉtablissement de santé
-
Ministry of Health of the Russian Federation pays non établi dans la noticeOrganisme public
-
Ulyanovsk Regional Clinical Hospital pays non établi dans la noticeÉtablissement de santé
-
National Medical and Surgical Center named after N.I. Pirogov pays non établi dans la noticeStructure de recherche
-
Nizhny Novgorod Regional Clinical Hospital named after Semashko pays non établi dans la noticeÉtablissement de santé
-
Research Institute of Fundamental and Clinical Immunology pays non établi dans la noticeÉtablissement de santé
-
Regional Clinical Research pays non établi dans la noticeStructure de recherche
-
Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan pays non établi dans la noticeÉtablissement de santé
-
Ivanovo State Medical Academy pays non établi dans la noticeÉtablissement de santé
-
Tula Regional Clinical Hospital pays non établi dans la noticeÉtablissement de santé
Krasnoyarsk State Medical University, City Clinical Hospital et Regional Clinical Hospital No 4, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.